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Abstract
Background: Indigenous women in Australia have a disproportionate burden of cervical cancer despite a national
cervical screening program. Prior to introduction of a national human papilloma virus (HPV) vaccination program,
we determined HPV genotype prevalence by Indigenous status and residence in remote areas.
Methods: We recruited women aged 17 to 40 years presenting to community-based primary health services for
routine Pap screening across Australia. A liquid-based cytology (LBC) cervical specimen was tested for HPV DNA using
the AMPLICOR HPV-DNA test and a PGMY09/11-based HPV consensus PCR; positive specimens were typed by reverse
hybridization. We calculated age-adjusted prevalence by weighting to relevant population data, and determined
predictors of HPV-DNA positivity by age, Indigenous status and area of residence using logistic regression.
Results: Of 2152 women (655 Indigenous), prevalence of the high-risk HPV genotypes was similar for Indigenous
and non-Indigenous women (HPV 16 was 9.4% and 10.5%, respectively; HPV 18 was 4.1% and 3.8%, respectively),
and did not differ by age group. In younger age groups, the prevalence of other genotypes also did not differ, but
in those aged 31 to 40 years, HPV prevalence was higher for Indigenous women (35% versus 22.5%; P < 0.001),
specifically HPV clades a5 (OR = 2.1, 95% CI 1.1 to 4.3) and a7, excluding type 18 (OR 1.9, 95% CI 1.1 to 3.3). In
multivariate analysis, detection of any HPV genotype was strongly associated with smoking and Pap-test
abnormalities, with both risk factors more common among Indigenous women.
Conclusion: Although we found no difference in the prevalence of HPV16/18 among Australian women by
Indigenous status or, for Indigenous women, residence in remote regions, differences were found in the
prevalence of risk factors and some other HPV genotypes. This reinforces the importance of cervical screening as a
complement to vaccination for all women, and the value of baseline data on HPV genotype prevalence by
Indigenous status and residence for the monitoring of vaccine impact.
Background
Since the introduction of a comprehensive, organized, cer-
vical cytology (Pap) screening program in 1991, Australia
has seen a marked reduction in incidence of cervical can-
cer from 13.2 per 100,000 in the early 1990s to a current
stable rate of around 6.9 per 100,000 since the early 2000s.
This has been matched by a mortality reduction from 4 to
1.9 per 100,000 for the respective time periods [1]. How-
ever, there are large disparities within the total Australia
population; incidence and mortality are higher for regional
and remote than urban residents, and much higher
(approximately two and five times higher respectively) for
Indigenous (Aboriginal and Torres Strait Islander women)
than other Australian women [1].
Cervical cancer is caused by oncogenic human papillo-
mavirus (HPV) types, [2] with 70% of cases due to HPV
16 and 18 genotypes both worldwide and in Australia
[3]. Given the early results of Phase 3 vaccine trials of a
bivalent [4] and quadrivalent vaccine [5,6], which have
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cervical disease, safety and immunogenicity, we
embarked on a study (the Women’sH P VI n d i g e n o u s
Non-Indigenous Urban Rural Study; WHINURS) to
compare the prevalence of genotype-specific HPV
among Indigenous and non-Indigenous women residing
in both remote and urban settings across Australia. The
primary aim was to establish whether there was any
substantive difference in the prevalence of specific HPV
genotypes, particularly vaccine-preventable genotypes,
prior to an HPV vaccination program, by region of resi-
dence and Indigenous status. This was based on prece-
dents in which such differences were present for other
infectious diseases [7-10] in these groups, as well as
some limited data from small surveys suggesting similar
differences for HPV [11].
Existing Australian data on cervical HPV prevalence in
the general population are limited, with either none or,
in one case, only small study datasets from subpopula-
tions included in international meta-analyses of preva-
lence in women with low-grade or normal cytology
[12-15]. Although these international data have indicated
that HPV16 is the most common HPV type detected
across the world, differences in the prevalence of the
next most common types have been noted between
regions. Few studies have been conducted to date directly
evaluating HPV types in Indigenous populations com-
pared with non-Indigenous populations. This is particu-
larly important given that Indigenous in many developed
countries that are already deploying HPV vaccines, such
as the US, Canada, Australia and New Zealand, have high
rates of cervical cancer. Should the prevalence of vac-
cine-preventable HPV types in Indigenous women differ
from those of non-Indigenous women, then there is a
risk that vaccination could widen rather than reduce
existing inequities in cervical cancer. This is further com-
pounded by the current lack of knowledge as to whether
non-vaccine types may become more prevalent (both in
absolute and relative terms) after vaccination. Only one
study has previously sought to determine possible differ-
ences between Indigenous and non-Indigenous Austra-
lian women in prevalence of specific HPV types [16].
Using tampon-collected specimens and an L1-based PCR
system capable of typing 10 HPV types, that study found
that non-Indigenous women had higher rates of HPV
detected (56% versus 42%): however the analysis did not
account for differences between the two groups in para-
meters such as sites of recruitment, cytology results or
age.
In April 2007, Australia commenced the most com-
prehensive government-funded national HPV vaccina-
tion program in the world, using the quadrivalent
vaccine for all girls 12-13 years of age as an ongoing
program, with a catch-up program delivered through
school and community providers for women up to
26 years of age, which finished on 31 December 2009.
The data from this study provide an important baseline
for comparisons internationally by epidemiologic setting
and ethnicity before and after the commencement of
widespread programs of HPV vaccination.
Methods
The aim of this study was to determine whether there
w e r ea n yd i f f e r e n c e si nH P Vt y p ep r e v a l e n c eb ya r e ao f
residence or ethnicity, and this aim guided our choice of
methods. Engagement and recruitment of Indigenous
women in remote areas, by providing the opportunity to
participate meaningfully in improving their own health
and that of their communities, was recognized as crucial
to the success of the study. Therefore, the sampling strat-
egy was guided by the use of methods that would include
these women in a culturally appropriate way.
Consultation, ethics, pilot site, and development of
culturally appropriate materials
In recognition of the need for research to benefit Indigen-
ous communities, and for Indigenous people to be
involved in the design, planning, undertaking and dissemi-
nation of Indigenous research, we identified collaborative
research partners involved in frontline community care
and service provision in the area of cervical cancer preven-
tion in Indigenous communities. Prior to initiation of the
study, we undertook consultation with Indigenous com-
munities (including the establishment of an Indigenous
Steering Committee), medical services, healthcare workers,
public-health practitioners and servicing cytology groups,
commencing in January 2005, including on-site workshops
and subsequent staff training. Protocols and communica-
tion materials (including flipcharts and brochures) were
developed to support the study, with local input at differ-
ent sites to tailor the materials so that they would be
locally and culturally appropriate as needed. A pilot study
was conducted in central Australia between April and July
2005 to examine feasibility, communication materials and
protocols, and laboratory techniques: it was endorsed by
the Central Australian Human Research Ethics Commit-
tee. The multisite study was approved by 34 site ethics
committees. Women were enrolled into the study between
July 2005 and February 2008.
Study population, recruitment methods, consent and
specimen collection
Women aged 18 to 40 years who were attending their
usual healthcare provider for routine Pap smear cytology
were invited to participate in the study. Some women aged
under 18 years, who were assessed as mature minors and
hence competent for giving consent without parental or
guardian involvement and attending for a routine Pap test,
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Australia see a general practitioner (primary-healthcare
providers) for Pap-test screening, our primary focus was
upon adequate recruitment of Indigenous women, and
therefore we targeted Indigenous health providers and
clinics, and equivalent service providers (community-
based, no fee for service) for non-Indigenous women, to
ensure comparability of Indigenous and non-Indigenous
women in the study. The study sample size was deter-
mined based on the HPV prevalence estimates from a
large community-based study in the USA of women aged
18-40 attending for a Pap smear and was powered (a =
0.05, 1-b = 0.90) to detect an absolute difference in
HPV16/18 of ≤ +/-5% between Indigenous and non-Indi-
genous women, and between Indigenous women residing
in remote areas and other Indigenous women [17]. We
determined the sample size necessary at each site accord-
ing to the predominant client population of the site (Indi-
genous or non-Indigenous) and the remoteness category
of the site according to the Accessibility/Remoteness
Index of Australia (ARIA). The ARIA assigns a ‘remote-
ness score’ based on each locality’s relative access to ser-
vices, which is estimated by road distance (or other
transport mechanism for islands) to the nearest population
centers of several different sizes. These scores are grouped
into five categories: major cities, inner regional, outer
regional, remote, and very remote. Approximately two-
thirds of the Australian population [18], but only one-
third of the Indigenous population, live in major cities [19]
We recruited women in all states and one territory
(Northern Territory) of Australia from sixteen Indigen-
ous health services, eight family-planning services and
ten community clinics. Owing to the incorporation of
the study into routine clinical care, response rates (num-
ber enrolled divided by number approached) were not
accurately recorded at all sites. Where response rates
were recorded or estimated from the number of eligible
(by age) women who had a Pap test taken during the
recruitment period, these ranged from 46% to 87%.
Recruitment of Indigenous women in some sites was
challenging, and required further strategies for commu-
nity engagement with the study to be developed [20,21].
Women were asked to allow the cervical samples col-
lected for Pap cervical cytology to be tested for HPV
DNA also. Once fully informed consent was obtained,
Pap smear samples were collected in the routine clinic
settings. In addition to routine pathology specimen
details, information confirming Indigenous status, most
recent previous Pap-test result, pregnancy status, smok-
ing status and hormonal contraceptive use was
requested from participants. Following the testing of
specimens, identifying details were used to report Pap
cytology and high-risk (HR) HPV DNA results back to
the clinician.
Most specimens were collected using a brush (Cervex;
Rovers Medical Devices BV, The Netherlands) and a spa-
tula. The sample was then smeared onto a glass slide and
fixed with ethanol ready for conventional Pap cytology,
and the remainder was rinsed into vials containing fixative
solution (ThinPrep vials with PreservCyt fixative; Cytyc
Corp., Boxborough, MA, USA). In a minority of samples,
LBC was standard, and hence an aliquot was removed
using good microbiological practices within a biohazard
cabinet, prior to processing for cytology. All samples were
transported to the Regional WHO LabNet for HPV
located at the Royal Women’s Hospital in Melbourne,
Australia, for HPV DNA detection and genotyping.
Algorithm for feedback of results and follow-up by
clinicians
Results of the HR HPV testing were returned to the
woman’s healthcare provider so that they could be con-
veyed back by trained staff to each participant in a cultu-
rally appropriate way. All women were managed according
to National Health and Medical Research Council guide-
lines for the follow-up of abnormal Pap tests [22]. Cur-
rently, HPV DNA testing in clinical practice in Australia is
only recommended as a “test-of-cure” following local abla-
tive or excisional therapy for precursor cervical cancer
lesions of high-grade (2+) cervical intraepithelial neoplasia
(CIN) [22].
HPV DNA detection and genotyping
DNA was extracted from stored specimens (in PreservCyt)
using a commercial isolation and purification system
(MagNA Pure LC; Roche Molecular Systems, Alameda,
CA, USAusing 1-ml aliquots of the preserved specimens
as previously described [23,24]. From a final volume of
100 μlo fr e s u l t a n tD N A ,1 0μl of extracted DNA was
screened (AMPLICOR HPV test; Roche Molecular Sys-
tems) for detection of 13 HR HPV genotypes (types 16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68). As this test
detects only 13 HR HPV types, all samples testing negative
for HR HPV by this test were also tested to exclude pre-
sence of other types, using a 20 μl aliquot of extracted
DNA in a PGMY09/11-based HPV consensus PCR assay
[25]. A PCR-ELISA detection protocol was used, as
described previously [26]. All assays used incorporated the
amplification of the b-globin gene as an internal control.
All samples that tested positive by the AMPLICOR or
PGMY09/11 PCR test were genotyped (HPV Linear
Array
® (LA) Genotyping Test; Roche Molecular Systems),
using 50 μl of extracted DNA, and following the manufac-
turer’s instructions with minor modifications as previously
reported [24,27,28]. LA identifies 37 genotypes: 6, 11, 16,
18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58,
59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82 (pre-
viously known as IS39), 83, 84 and 89 (previously known
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weakly positive only to the PGMY09/11 PCR but negative
on LA, and these specimens were classified as HPV
negative.
Specimen contamination and carryover were pre-
vented by use of barrier tips, prior division of all
reagents into aliquots, and performance of pre- and
post-PCR steps in different rooms specifically allocated
for PCR. Negative and positive controls were processed
with each run, and lack of signal in the negative control
was used to monitor possible carryover.
Statistical analysis
The ARIA category was assigned using the postcode of
each participant’s residence. Pap-test results were
reported by cytology laboratories (usual service provi-
ders) according to the Australian Modified Bethesda clas-
sification, 2004 [22]. For the purposes of analysis,
‘possible’ low-grade squamous intraepithelial lesion
(LSIL) Pap results were grouped LSIL and ‘possible’ high-
grade squamous intraepithelial lesion (HSIL) Pap results
were grouped with HSIL.
Age-adjusted prevalences were calculated by weighting
the WHINURS sample to the relevant Australian Bureau
of Statistics (ABS) population structure, by single year of
age. Data were analyzed using SPSS software (version 17.0;
SPSS Inc., Chicago, IL, USA), except for weighted confi-
dence intervals, which were calculated using STATA soft-
ware (StataCorp LP, College Station, TX, USA). Univariate
analysis compared proportions using Pearson’s c
2 tests (or
Fisher’s exact test when the expected count in any cell was
< 5), and mean ages using t-test. Binary logistic regression
was used for multivariate analysis. Interaction terms were
created for predictor variables to check for effect modifica-
tion. No significant interactions were identified. Because of
the high correlation between living in a remote area and
Indigenous status, the effect of area of residence was ana-
lyzed separately for the two groups of women, with the
analysis of non-Indigenous women comparing residence
in a major city versus non-major city.
Indigenous status and area of residence were variables of
prior interest. Multivariate models also included other
known determinants of HPV infection: age, smoking sta-
tus, and use of hormonal contraception. We did not col-
lect sexual history from participants. Although some
women were pregnant, there was no association between
pregnancy and HPV detection in univariate analysis, and
hence this was not considered further.
Results
Of a total of 2156 samples from women age 15 to 40 years,
four were found to have no ß-globin signal, indicating
inadequate sample collection, and these were excluded
from the analysis, leaving 2152 participants with HPV
results available (655 Indigenous, 1494 non-Indigenous,
3 unknown ethnicity) (Table 1). Half of the Indigenous
participants were recruited from remote or very remote
areas, compared with 6% of the non-Indigenous
participants.
Characteristics of participants
Regarding demographic variables, Indigenous women were
more likely to be younger, to smoke, to be pregnant and
less likely to use hormonal contraception (Table 1).
Regarding Pap-test-related variables, a higher proportion
of Indigenous than non-Indigenous women were having
their first ever Pap test (13.8% versus 10.1%; P = 0.02), and
the prevalence of abnormal Pap-test results was higher.
T h ep r e v a l e n c eo fH S I La sp r e d i c t e db yc y t o l o g yw a s
higher for Indigenous than non-Indigenous women for
both their most recent previous Pap test (1.4% versus
0.4%, P = 0.02), and for the Pap test performed during this
study (current Pap test) (4.0% versus 1.4%, P < 0.001). Of
the 45 women with a current high-grade abnormal Pap
test, 25 (56%) were Indigenous, including one with squa-
mous cell carcinoma and one with possible microinvasive
cancer.
Demographic differences between Indigenous women
from remote compared with non-remote areas were small
and not significant, with one exception: a higher propor-
tion of women from remote areas had normal results on
their most recent previous Pap test compared with women
from non-remote areas (93.8% versus 85.8% of women for
whom the previous Pap result was known, P = 0.003)
(Table 1). To evaluate the representativeness of our sam-
ple, we compared the prevalence of abnormal Pap tests in
non-Indigenous study participants with data from the Vic-
torian Cervical Cytology Registry (which services women
resident in the state of Victoria, Australia, representing a
population of 2.7 million women) on the age-adjusted pre-
valence of abnormal Pap tests among resident women
aged 15-39 (national data were not available). The age-
adjusted prevalences for the study population and for
women in Victoria were similar: respectively, 88.2% and
88.9% for normal Pap tests; 10.4% and 9.5% for LSIL; and
1.3% and 1.7% for HSIL/cancer.
Cervical HPV DNA prevalence
The age-adjusted prevalence of detection of any HPV
DNA was higher for Indigenous than for non-Indigen-
ous women when standardized to the general Australian
population, although confidence intervals overlapped
(Table 2). However, there was no significant or clinically
relevant difference in the prevalence of vaccine-preven-
table types. It should be noted that overall, 1.7% of the
AMPLICOR positives could not be confirmed by LA
and the in-house assay, hence these were deemed as
negative on genotyping.
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genous and non-Indigenous women, with types 51, 52,
18 and 39 being the other four most common high-risk
types in both groups (Table 3). There was a significant
difference in the prevalence of HPV68 (a high-risk type)
between Indigenous and non-Indigenous women (OR =
3.8, 95% CI 1.9 to 7.6; P < 0.001), although caution is
needed in interpreting this finding given the multiple
comparisons of genotype groups performed.
Among Indigenous women, the high-risk types HPV56
and HPV58 were detected more frequently in women
living in remote areas (HPV56 3.6% versus 1.2%, P =
0.05; and HPV58 4.5% versus 1.5%, P=0.03), whereas
the high-risk type HPV59 was found more frequently in
women living in non-remote areas (5.2% versus 1.5%,
P = 0.008). The low-risk (LR) types HPV71 and HPV72
were found in women in remote areas (each in 2.1%;
P = 0.015). HPV81 was also more common among
women in remote areas (6.1% versus 2.8%; P =0 . 0 4 ) .
Again, caution is needed in interpreting these findings,
because of the multiple comparisons.
Association of age with HPV detection
The prevalence of HPV infection was much higher in
younger than older women (Figure 1A). The prevalence
of genotypes 16 and 18 was similar for Indigenous and
non-Indigenous women in each age group. For other
genotypes (HR, probable HR and LR HPV), the preva-
lence was similar for Indigenous and non-Indigenous
w o m e ni ny o u n g e ra g eg r o u p s ,b u th i g h e rf o rI n d i g e n -
ous than non-Indigenous women in the 31 to 35 and 36
to 40 years age groups (Figure 1B, C), with 35% of Indi-
genous and 22.5% of non-Indigenous 31 to 40-year-old
women positive for HPV types other than 16 or 18 (OR
= 1.9, 95% CI 1.3 to 2.6, P < 0.001). Excluding women
with an abnormality on the most recent previous or the
current Pap test gave a similar result (Table 4).
In the 36 to 40 years age group, 39.4% of Indigenous
women had detectable HPV (any HPV genotype) com-
pared with 22.1% of non-Indigenous women (OR = 2.3,
P < 0.001). The higher HPV prevalence for Indigenous
women was partly explainedb yah i g h e rp r e v a l e n c eo f
HPV risk factors. In this age group, Indigenous and
non-Indigenous women had similar distribution of age
by single year (mean age 37.9 versus 38.0, P =0 . 4 ,
t-test) and hormonal contraceptive use (22.4% versus
25.1%, P = 0.6), but Indigenous women were more than
twice as likely to smoke (45.9% versus 21.8%, P < 0.001)
and more than seven times as likely to have a current
high-grade Pap-test result (3.1% versus 0.4%; P = 0.03)
or to be having their first ever Pap (n = 3 (3.2%) versus
n = 1 (0.4%), P = 0.03). Adjusting in multivariate ana-
lyses for age, hormonal contraceptive use, smoking, low-
grade Pap-test results and most recent previous Pap sta-
tus reduced, but did not eliminate, the excess risk of
HPV detection for Indigenous women (OR = 1.8, 1.03
to 3.2; P = 0.04). High-grade results were too infrequent
to be included in this model.
Detection of multiple HPV types
Overall, 57.6% of HPV-positive non-Indigenous women
and 55.6% of HPV-positive Indigenous women had mul-
tiple types detected. However, infection with multiple
types was less prevalent with increasing age (Figure 2).
Table 1 Demographic characteristics of WHINURS
a
participants aged ≤40 years, by Indigenous status
b
Variable Non-
Indigenous
Indigenous
n% n %
Participants 1494 655
Age, years
15 to 20 139 9.3% 117 17.9%
21 to 25 359 24.0% 178 27.2%
26 to 30 383 25.6% 137 20.9%
31 to 35 341 22.8% 124 18.9%
36 to 40 272 18.2% 99 15.1%
Median 29 27
Mean
c 28.9 27.4
Hormonal contraception user
c,d 643 43.3% 196 30.3%
Smoker
c,e 368 24.8% 363 56.2%
Pregnant
c,f 13 0.9% 54 8.2%
Remoteness
g
Major cities 868 58.1% 45 6.9%
Inner regional 182 12.2% 65 9.9%
Outer regional 351 23.5% 215 32.8%
Remote 78 5.2% 135 20.6%
Very remote 15 1.0% 195 29.8%
Most recent Pap-test result
b
Normal 1143 81.2% 453 77.3%
Low-grade abnormality 116 8.2% 44 7.5%
High-grade abnormality 5 0.4% 7 1.2%
First Pap 144 10.2% 82 14.0%
Unknown/missing/unsatisfactory 19/45/22 21/42/6
Current Pap-test result
b,f
Normal 1296 88.0% 527 84.7%
Low-grade abnormality 156 10.6% 70 11.3%
High-grade abnormality
b 20 1.4% 25 4.0%
Unsatisfactory 20 7
aWomen’s HPV Indigenous Non-Indigenous Urban Rural Study.
bThree participants with unknown Indigenous status are not included in this
table.
bP < 0.001 for group Indigenous women versus non-Indigenous women.
cData missing for ten non-Indigenous and eight Indigenous participants.
dData missing for ten non-Indigenous and nine Indigenous participants.
eData missing for eight non-Indigenous and six Indigenous participants.
fData missing for two non-Indigenous and twenty-six Indigenous participants.
gRemote residence refers to residence in an area categorized as remote or
very remote using the Accessibility/Remoteness Index of Australia
classification by postcode. Non-remote residence refers to areas categorized
as major cities or regional areas.
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for Indigenous than non-Indigenous women in the 36-
40 years age group, the proportion of infected women
with multiple infections was similar (Indigenous 38.5%,
non-Indigenous 36.7%, P = 0.9).
In a multivariate analysis of HPV-positive women
(including Indigenous status, age, hormonal contracep-
tion, smoking, most recent previous Pap status, current
Pap status), only younger age (for each year’s increase in
age: OR = 0.939, 95% CI 0.918 to 0.961, P < 0.001) and
having a low-grade Pap abnormality on current Pap test-
ing (OR 1.9, 95% CI 1.4 to 2.8, P < 0.001) were signifi-
cantly associated with the detection of multiple HPV
types.
Predictors of cervical HPV detection
As expected, having a current abnormality on a Pap test
was strongly associated with HPV DNA detection (HPV
DNA detected in 97.8% of cases with HSIL (OR = 76,
P < 0.001) and 85.9% LSIL (OR = 10, P < 0.001). Having
had an abnormality on the previous Pap test was also
strongly associated with HPV DNA detection (HPV
DNA detected in 70% of cases; OR = 3.4, P < 0.001).)
All variables of interest were significantly associated
with the detection of any HPV DNA in univariate analy-
sis (Table 5). In multivariate analysis, Indigenous status
and hormonal contraceptive use became non-significant.
In the stratified analysis, remote area of residence was
not a significant predictor of any HPV DNA detection
for Indigenous women in either univariate or multivari-
ate analyses (data not shown). However, for non-Indi-
genous women, residence outside of a major city was
associated with a lower risk of any HPV detection (35%
versus 46%; OR = 0.6, 95% CI 0.5 to 0.8, P <0 . 0 0 1 ) ,
which remained significant in multivariate analysis
(OR = 0.6, 95 CI 0.5 to 0.8, P < 0.001).
In both univariate and multivariate analyses, age,
smoking and hormonal contraceptive use were all asso-
ciated with HPV16/18 detection (Table 6). Indigenous
status was not associated with HPV16/18 detection. In
stratified analyses including only Indigenous women,
Table 2 Crude and age-adjusted cervical human papillomavirus (HPV) DNA prevalence and prevalence of multiple HPV
infections by Indigenous status (note ‘/’ denotes ‘and/or’)
a
HPV Prevalence Non-Indigenous, 15 to 40 years of age
(n = 1494)
Indigenous, 15 to 40 years of age
(n = 655)
Age-adjusted
b HPV prevalence Age adjusted to Australian
population
a
Indigenous
population
c
HPV16/18 12.8% (10.8 to 14.8) 12.2% (9.7 to 14.6) 13.8% (11.1 to 16.6)
HPV genotypes 6/11/16/18 15.3% (13.3 to 17.4) 14.1% (11.5 to 16.7) 15.9% (13.1 to 18.8)
Cross-protection 16/18/31/45 17.1% (14.9 to 19.3) 15.6% (12.9 to 18.3) 17.4% (14.4 to 20.4)
HR
d HPV 13 types
e 30.0% (27.5 to 32.3) 31.3% (27.7 to 34.9) 33.2% (29.5 to 36.8)
HR HPV 18 types
f 33.5% (31.0 to 36.0) 35.4% (31.8 to 39.1) 37.5% (33.8 to 41.2)
HR HPV-11 types (non-16/18) 23.7% (21.3 to 26.1) 25.9% (22.4 to 29.3) 27.3% (23.8 to 30.9)
HR HPV-16 types (non-16/18) 28.6% (26.1 to 31.0) 30.6% (27.1 to 34.2) 32.3% (28.6 to 36.0)
Any HPV 41.5% (38.9 to 44.1) 47.5% (43.6 to 51.3) 49.3% (45.5 to 53.2)
LR
g HPV 24.8% (22.3 to 27.2) 28.7% (25.2 to 32.2) 30.1% (26.5 to 33.7)
LR only present 8.0% (6.6 to 9.39) 12.0% (9.41 to 14.7) 11.9% (9.3 to 14.5)
HPV genotypes 6/11/16/18 only 3.5% (2.6 to 4.5) 3.5% (2.1 to 5.0) 4.0% (2.3 to 5.6)
Multiple HPV types (crude
prevalence)
Range (min-max) 0 to 13 0 to 10
None 58.8% (56.3 to 61.3) 50.5% (46.6 to 54.5)
One 17.5% (15.6 to 19.5) 22.0% (18.8 to 25.3)
Two 9.1% (7.7 to 10.7) 12.4% (9.9 to 15.1)
Three 7.0% (5.7 to 8.4) 5.8% (4.1 to 7.9)
Four or more 7.6% (6.3 to 9.1) 9.3% (7.2 to 11.8)
aData are % (95% CI exact binomial), unless otherwise stated.
bAge-standardized to the Australian female population aged 17 to 40 years, 2005, Australian Bureau of Statistics (NB there were only eight women aged 15t o
16 years.)
cAge-standardized to the Australian Indigenous female population aged 17 to 40 years, 2005, unpublished experimental estimates, Australian Bureau of Statistics.
Single year of age experimental Indigenous population estimates may be subject to errors that cannot be fully adjusted for in the population estimates
compilation process.
dHR = high-risk.
eHR HPV types 16,18,31,33,35,39,45,51,52,56,58,59,68.
fAs above plus HPV types 26,53,66,73 and 82.
gLR = low-risk.
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Page 6 of 13HPV16/18 detection was not associated with residence
in a remote area, in either univariate or multivariate
analyses (data not shown). In the stratified analysis of
non-Indigenous women, women residing outside of
major cities were significantly less likely to have HPV16/
18 detected (9.7% versus 14.3%, P = 0.001); this variable
remained significant in the adjusted analysis (OR = 0.6,
95 CI 0.5 to 0.9, P = 0.01).
Discussion
This study of Australian women presenting for routine
Pap testing prior to the introduction of the National
HPV Vaccination Program found HPV16 to be the most
prevalent HPV genotype in Indigenous and non-Indi-
genous Australian women equally, and that the five
most common high-risk types were the same in both
groups. Detection of any HPV genotype was strongly
associated with smoking, Pap-test abnormalities and
younger age. Indigenous women living in remote areas
did not have more HPV genotypes detected, or more or
fewer vaccine-preventable types, but for non-Indigenous
women, living in a major city was associated with a
higher probability of having HPV detected, and for that
type to be 16 or 18. Marked differences in the preva-
lence of HPV between Indigenous and non-Indigenous
women were not found, although older Indigenous
women (31 to 40 years old) had more non-HPV 16/18
types detected. The dominance of HPV16 is consistent
with worldwide prevalence studies, but HPV51, the sec-
ond most common high-risk type we detected, does not
have such a high prevalence globally [15].
It is unclear why Indigenous women in their 30s had
higher rates of non-HPV16/18 genotype carriage. Indi-
genous Australian women have a different demographic
profile to non-Indigenous women, as also reflected in our
recruited sample, in ways which could have an effect
upon their likelihood of HPV infection, that is, younger
age, more than twice as likely to smoke, and a higher fer-
tility rate [19]. Indigenous women also have higher rates
of other sexually transmitted infections (STIs) [10], and
an earlier age at first sexual intercourse [30]. More Indi-
genous women also live in poverty [19,31], and greater
persistence of HPV due to failure of immunological con-
trol could be in part attributable to the effects of lower
socioeconomic status or general health status, in combi-
nation with high rates of smoking, earlier and more preg-
nancies, and the presence of other STIs. It could also
reflect poorer access to cervical cytology screening by
Indigenous women in this age group: this has been
hypothesized to be an important factor in the higher
Table 3 Human papillomavirus (HPV) types in women
≤40 years by Indigenous status, n (%)
HPV type Non-Indigenous
women
(n = 1494)
Indigenous
women
(n = 655)
6 47 (3.1%) 13 (2.0%)
11 9 (0.6%) 6 (0.9%)
16
a 141 (9.4%) 69 (10.5%)
18
a 62 (4.1%) 25 (3.8%)
2 0 1 (0.2%)
31
a 56 (3.7%) 22 (3.4%)
33
a 31 (2.1%) 18 (2.7%)
35
a 16 (1.1%) 14 (2.1%)
39
a 58 (3.9%) 24 (3.7%)
40 16 (1.1%) 4 (0.6%)
42 61 (4.1%) 19 (2.9%)
45
a 23 (1.5%) 15 (2.3%)
51
a 94 (6.3%) 37 (5.6%)
52
a 57 (3.8%) 36 (5.5%)
53 82 (5.5%) 34 (5.2%)
54 49 (3.3%) 24 (3.7%)
55 29 (1.9%) 8 (1.2%)
56
a 39 (2.6%) 16 (2.4%)
58
a 44 (2.9%) 20 (3.1%)
59
a 39 (2.6%) 22 (3.4%)
61 56 (3.7%) 33 (5.0%)
62 65 (4.4%) 35 (5.3%)
64 1 (0.1%) 0
66 61 (4.1%) 23 (3.5%)
67 24 (1.6%) 8 (1.2%)
68
a,b 13 (0.9%) 21 (3.2%)
69 1 (0.1%) 4 (0.6%)
70
b 21 (1.4%) 28 (4.3%)
71
b 1 (0.1%) 7 (1.1%)
72
c 2 (0.1%) 7 (1.1%)
73 40 (2.7%) 21 (3.2%)
81
b 20 (1.3%) 29 (4.4%)
82 (previously IS39) [29] 20 (1.4%) 10 (1.6%)
83 19 (1.3%) 15 (2.3%)
84 61 (4.1%) 19 (2.9%)
89 (previously CP6108)
[29]
68 (4.6%) 31 (4.7%)
No type detected
b 879 (58.8%) 332 (50.6%)
Multiple 354 (23.7%) 180 (27.4%)
16/18 185 (12.5%) 86 (13.1%)
6/11/16/18 220 (14.7%) 102 (15.5%)
16/18 only 44 (2.9%) 21 (3.2%)
6/11/16/18 only 53 (3.5%) 26 (4.0%)
aEstablished high-risk HPV type.
bc
2 P < 0.001.
cc
2 P = 0.002.
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Page 7 of 13rates of cervical cancer incidence and mortality observed
in Indigenous women [21,32]. Franceschi et al. previously
found that lower education levels (as a proxy for socioe-
conomic status) are correlated with cervical cancer risk
but not increased HPV prevalence, and may be mediated
through risk factors such as earlier age at first inter-
course, and higher and earlier parity [33]. Regardless of
the underlying reasons, the presence of other high-risk
HPV DNA types among women in their 30s clearly
emphasizes the need for participation in cervical screen-
ing, whether or not a woman has received HPV vaccina-
tion. It should be noted that for this population up to 40
years, the Indigenous women had a U-shaped curve of
HPV prevalence. This has also been described in other
populations, with hypotheses for its occurrence including
changes in sexual behaviour with age, reactivation of
latent infection and a cohort effect [34].
The rates of absolute HPV prevalence, frequent occur-
rence of multiple HPV types and high rates of HPV DNA
detected in young women are all consistent with other stu-
dies of screening populations in western countries using
similar highly sensitive assays (as opposed to clinically
adapted assays such as Hybrid Capture 2) [17,35-37].
There are three main limitations to our study. Firstly,
we did not collect a sexual or reproductive history from
participants. This means we cannot use this established
predictor to determine whether women recruited were
more or less likely than other Australian women to have
HPV. Clearly, however, all women participating in the
study were sexually active, and should have been so for
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Figure 1 (A-C): Prevalence of human papilloma virus (HPV) by age group and Indigenous status. (A) HPV16 or 18; (B) 11 high-risk HPV
types without 16/18; (C) low-risk and possible high-risk HPV types.
Table 4 Cervical human papillomavirus (HPV) prevalence
a
by Indigenous status and age group
Pap status and age group Indigenous Non-Indigenous
n%n % P value
All women
15 to 20 117 67.5 139 64.0 0.6
21 to 25 179 56.4 359 54.0 0.6
26 to 30 137 39.4 383 43.6 0.4
31 to 35 124 41.1 341 30.8 0.04
36 to 40 99 39.4 272 22.1 0.001
Women with normal results
b
15 to 20 90 61.1 99 52.5 0.2
21 to 25 123 46.3 255 44.7 0.8
26 to 30 105 33.3 323 37.5 0.4
31 to 35 98 34.7 298 25.5 0.08
36 to 40 84 33.3 240 18.3 0.004
aPrevalence of any HPV genotype,
bCurrent Pap test and most recent Pap-test results not known to be abnormal.
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Page 8 of 13at least two years, given that screening guidelines in
Australia recommended Pap testing commence at the
age of 18 years or 2 years after first sexual intercourse,
whichever is later. Secondly, because our main focus
was to recruit adequate numbers of women in remote
area and of Indigenous women, our sample is not geo-
graphically or demographically representative of all
Australian women. Non-Indigenous women attending
23.1% 24.6%
16.1%
21.8% 24.2%
44.4%
31.8%
23.4%
19.4% 15.2%
18.0% 19.2% 20.6%
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<21 21-25 26-30 31-35 36-40
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Non-Indigenous multiple HPV
Non-Indigenous single HPV
Indigenous multiple HPV
Indigenous single HPV
Figure 2 Percentage of women with single and multiple cervical human papillomavirus (HPV) DNA detection by age group and
Indigenous status.
Table 5 Univariate and multivariate associations with detection of any human papillomavirus (HPV) type, all women
aged ≤40 years (n = 2152)
Variable Any HPV-positive, % OR (95%CI) P value Adjusted OR (95%CI) P value
Indigenous
a
Yes 49.4% 1.4 (1.2 to 1.7) < 0.001 1.1 (0.9 to 1.4) 0.3
No 41.2%
Smoking
b
Yes 51.8% 1.6 (1.4 to 2.0) < 0.001 1.4 (1.2 to 1.8) < 0.001
No 39.5%
Age, years
c 0.915 (0.902 to 0.929) < 0.001 0.921 (0.908 to 0.935) < 0.001
Age, 5-year bands
< 21 years 65.8% 5.3 (3.7 to 7.5) < 0.001 Modeled as continuous variable as above
21 to 25 years 54.8% 3.3 (2.5 to 4.4)
26 to 30 years 42.6% 2.0 (1.5 to 2.7)
31 to 35 years 33.5% 1.4 (1.0 to1.9)
36 to 40 years 26.7% Reference
HC
d
Yes 47.0% 1.25 (1.05 to 1.49) 0.01 1.1 (0.9 to 1.3) 0.3
No 41.5%
aThree missing.
bTwenty-one missing.
cFor each one year increase in age.
dTwenty missing. HC = hormonal contraception
Garland et al. BMC Medicine 2011, 9:104
http://www.biomedcentral.com/1741-7015/9/104
Page 9 of 13free community health services are likely to be of lower
socioeconomic status on average than other Australian
women. However, the results were stratified by Indigen-
ous status and ARIA status within the two groups of
women, with similar recruitment of health services for
both Indigenous and non-Indigenous women, allowing
for comparison between the two groups. The non-Indi-
genous women we enrolled had smoking rates similar to
those of the women in the general Australian population
(in 2004/5, 27% of women aged 25 to 35 years were
smokers) [38], similar rates of oral contraceptive (OC)
use (63% and 32% of sexually active women aged 20 to
29 and 30 to 39 years, respectively, used OCs in 2001)
[39] and similar rates of Pap abnormalities. Lastly, 38
women recruited to our study (1.8%) were eligible
because of their age (aged up to 26 years) at the time of
recruitment to have received government-funded HPV
vaccination. We did not know their HPV vaccination
status, but only six of these women could theoretically
have finished a complete HPV vaccine course (4 months
after 1 July) at the time of Pap collection. These small
numbers of vaccine-eligible women could not influence
the study findings.
A truly population-based HPV DNA prevalence survey
of women pre-vaccination in Australia was not feasible for
several reasons. A random sample of women screened in
the national program was not possible because the
national program uses conventional dried slides rather
than LBC. Under Australian legislation, the slide must be
retained for a minimum of 10 years, but testing for HPV
involves destruction of the slide. Women who choose to
have LBC in Australia have to pay privately for the test,
and are not therefore a representative sample. Australia
currently has no national health survey with a biological
sample collection component (for example, urine sample
or vaginal swab) which could otherwise form a sample
frame for HPV testing of other suitable (although probably
less sensitive) sample types, as has been conducted in the
UK (urine) and USA (vaginal swab) [40]. Although the
first such survey with a biological sampling component is
planned for 2011, it is explicitly stated that no STI testing
is permissible within the survey framework [41].
Taken together with baseline HPV seroprevalence data
for Australia, [42] the WHINURS study data provides an
important baseline data set for Australia pre-vaccination.
Consistent with WHO recommendations for post-vaccina-
tion surveillance systems [43], studies are underway to use
WHINURS sites as sentinel sites for post-vaccination
surveillance, with identical recruitment methods, sample
collection and typing methods used, to allow comparison
between pre- and post-vaccination type-specific HPV pre-
valence in young women presenting for Pap testing.
Conclusions
In conclusion, we found no evidence that HPV16/18
prevalence differs significantly for Australian women
according to their Indigenous status or, for Indigenous
women, whether they lived in remote areas. However,
we did identify differences in risk-factor prevalence and
in the prevalence of some other HPV genotypes. Indi-
genous Australian women currently have higher rates of
cervical cancer, probably due to factors such as smoking,
Table 6 Univariate and multivariate associations with detection of human papillomavirus (HPV) types 16 or 18, all
women ≤40 years (n = 2152)
Variable Any HPV-positive, % OR (95%CI) P value Adjusted OR (95%CI) P value
Indigenous
a
Yes 13.1% 1.1 (0.8 to 1.4) 0.64 0.8 (0.6 to 1.1) 0.2
No 12.4%
Smoking
b
Yes 16.0% 1.6 (1.2 to 2.0) 0.001 1.4 (1.1 to 1.9) 0.01
No 10.9%
Age, years
c - 0.879 (0.858 to 0.900) < 0.001 0.884 (0.862 to 0.906) < 0.001
Age, 5-year bands 28.4% 10.9 (5.9 to 20) < 0.001 Modeled as continuous variable as above
< 21 years 18.0% 6.1 (3.3 to 11)
21 to 25 years 12.1% 3.8 (2.1 to 7.0)
26 to 30 years 5.6% 1.6 (0.8 to 3.2)
31 to 35 years 3.5% Ref
HC
d
Yes 17.4% 2.0 (1.5 to 2.6) < 0.001 1.7 (1.3 to 2.2) < 0.001
No 9.6%
aThree missing.
bTwenty-one missing.
cFor each one year increase in age.
dTwenty missing. HC = hormonal contraception
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Page 10 of 13higher fertility and lower rates of participation in cervi-
cal screening. This reinforces the importance of cervical
screening as a complement to vaccination for all
women, and the value of baseline data on HPV genotype
prevalence by Indigenous status and residence for moni-
toring of the effect of a vaccine program.
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